All News

The drug application was granted the FDA’s Priority Review designation, as well as a Tropical Disease Priority Review Voucher under a program intended to encourage development of new drugs and biologics for the prevention and treatment of certain tropical diseases.

The organization awarded the title to these heath care professions in recognition of the excellence achieved in pharmacy practice, according to the organization.

Novo Nordisk announced the results of the ELLIPSE trial, which examined efficacy and safety and demonstrated superiority of liraglutide (Victoza) injection 1.8 mg vs placebo, in a presentation at the Pediatric Endocrine Society (PES)/Pediatric Academic Societies (PAS) Annual Meeting in Baltimore, MD, on Sunday.